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Accumulating evidence suggests that dual-specificity tyrosine-regulated kinase 2 (DYRK2) functions as a tumor suppressor by regulating cell survival, differentiation, proliferation and apoptosis. However, little is known about the mechanisms of transcriptional regulation by DYRK2 in cancer progression, particularly with respect to cancer proliferation and invasion. Here, using a comprehensive expression profiling approach, we show that cyclin-dependent kinase 14 (CDK14) is a target of DYRK2. We found that reduced DYRK2 expression increases CDK14 expression, which promotes cancer cell proliferation and invasion in vitro, in addition to tumorigenicity in vivo. CDK14 and DYRK2 expression inversely correlated in human breast cancer tissues. We further identified androgen receptor (AR) as a candidate of DYRK2-dependent transcription factors regulating CDK14. Taken together, our findings suggest a mechanism by which DYRK2 controls CDK14 expression to regulate tumor cell proliferation and invasion in breast cancer. Targeting of this pathway may be a promising therapeutic strategy for treating breast cancer.
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| INTRODUCTION
Breast cancer is one of the most common malignancies for women worldwide. From 1980 to 2010, the annual incidence and mortality rates for breast cancer increased 3.1% and 1.8%, respectively. Dual-specificity tyrosine-regulated kinase 2 (DYRK2) is a protein kinase that phosphorylates its substrates at serine and threonine residues. Initially, DYRK2 was found to phosphorylate p53 at Ser46 to regulate apoptotic cell death in response to DNA damage. 2, 3 We in breast cancer and ovarian cancer. 5, 6 Recently, we reported for the first time that DYRK2 inhibits breast cancer stem cells through transcriptional downregulation of KLF4. 8 However, the mechanism of direct transcriptional regulation by DYRK2 in cancer progression, particularly in cancer proliferation and invasion, remains unclear.
In this study, we comprehensively searched for downstream target genes of DYRK2 using microarray analyses. Silencing of DYRK2 resulted in increased mRNA levels of cyclin-dependent kinase 14 (CDK14). CDK14, also known as PFTTAIRE1 or PFTK1, is a cell division cycle 2 (Cdc2)-related serine/threonine protein kinase that promotes cell cycle progression. 9 CDK14 shows high expression in the human brain, pancreas, kidneys, heart, testes and ovaries. 10 It is also reported that CDK14 promotes cancer progression and chemotherapy resistance in breast cancer, gastric cancer, ovarian cancer, esophageal cancer and hepatocellular carcinoma. 
| Cell transfection
Plasmids were transfected using X-tremeGENE HP DNA Transfec- (500 lg/mL). Gene knockdown and overexpression were assessed by real-time RT-PCR.
| Plasmid construction
pSuper-puro DYRK2 shRNA was constructed as described previously. 5 The sequences of shRNA targeting CDK14 were designed based on those of CDK14 siRNA. CDK14 shRNA were annealed and cloned into pSuper-neo vector (Oligoengine) according to the manufacturer's instructions. GFP-tagged DYRK2 was constructed as described previously. GSE75918. 
| Western blotting

| Real-time RT-PCR
Isolation of total RNA from cells was performed using TRIsure (Nippon Genetics, Tokyo, Japan). Total RNA was reverse transcribed into cDNA using the PrimeScript 1st strand cDNA Synthesis Kit (Takara, Shiga, Japan) according to the manufacturer's protocol. PCR was performed using KAPA SYBR FAST qPCR Master Mix (29) ABI Prism (Kapa Biosystems, Wilmington, MA, USA) according to the instruction manual. The data were normalized to the input control, b-actin or GAPDH.
| MTS assay
Cells were seeded into 96-well plates. 3-(4,5-dimethylthiazol-2-yl)-
salt (MTS) assays were performed using the CellTiter 96 AQ One Solution Cell Proliferation Assay Kit (Promega) according to the manufacturer's instructions. The absorbance was measured at 490 nm.
| Colony formation assay
MCF-7 cells or MDA-MB-231 cells were seeded into 6-well culture plates at a density of 4000 cells/well or 500 cells/well, respectively.
Cells were then cultured at 37°C in a 5% CO 2 incubator. Cells were washed with chilled PBS and fixed with 70% ethanol for 30 min at À20°C. After fixation, cells were stained using Giemsa Solution (Wako) for 10 min at room temperature. The cells were then washed with PBS twice.
| Invasion assay
Invasion assays were performed using the CytoSelect 24-Well Cell
Invasion Assay Kit (Cell Biolabs, San Diego, CA, USA) according to the instruction manual. Invasive cancer cells were stained, extracted and quantified at optical density (OD) 560 nm. Images were obtained using phase contrast microscopy (BZ-X700; Keyence, Osaka, Japan). 
| Xenograft studies
| Upstream transcription factor detection
A promoter analysis was performed using the online tool ExPlain 3.1
(http://explain.biobase-international.com/) to detect overrepresented transcription factor binding sites in MCF-7 DYRK2 siRNA cells compared to MCF-7 control siRNA cells (GSE75917). Seventy-six transcription factors were predicted to have putative binding sites in the promoters of genes suspected to be downstream targets of DYRK2 as described previously. 8 
| MAPPER database analysis
To identify transcription factors that have binding sites within 3 kb upstream of CDK14, the MAPPER database was used (http://ge nome.ufl.edu/mapper). 16 This identified 1153 putative binding sites and 370 genes in the promoter region of CDK14. probes that were more than 1.5-fold increased compared to controls in stable and transiently DYRK2-depleted cells, respectively. These two data analyses revealed that eight genes were upregulated in DYRK2-depleted cells ( Figure 1A ; Table S1 ). MCF-7 cells were transfected with two different siRNA or pSuper-puro shRNA targeting DYRK2 to exclude off-target effects. Ultimately, one probe was selected that was transcriptionally elevated in a DYRK2-dependent manner in both stably and transiently knocked-down cells. The analysis of microarray data indicated that the induction of CDK14 expression in DYRK2-depleted cells was significantly higher than that of control cells (Figure 1B,D) . Moreover, CDK14 was the most upregulated gene in stable DYRK2-depleted cells (Table S1 ). We 
| Dual-specificity tyrosine-regulated kinase 2 expression inversely correlates with tumor cell proliferation
Knocking down DYRK2 accelerated cell growth in MCF-7 cells (Figure 2A,B) . To elucidate the effects of DYRK2 overexpression in a cell line that normally expresses low levels of DYRK2, we generated a stable DYRK2-overexpressing MDA-MB-231 cell line using GFP-
DYRK2 (GFP-DYRK2 cells). A GFP vector was transfected as a vehi-
cle control (GFP control cells). The mRNA and protein levels of CDK14 in GFP-DYRK2 cells was significantly lower than that of GFP control cells (Figure 2C,D) . The proliferative ability of GFP-DYRK2 cells was significantly lower than that of GFP control cells (Figure 2E,F) . These results suggest that DYRK2 suppresses tumor cell proliferation.
3.3 | Tumor cell proliferation and invasion are regulated by dual-specificity tyrosine-regulated kinase 2 via cyclin-dependent kinase 14 expression
Our previous study showed that silencing of DYRK2 in MCF-7 cells enhanced cell invasion. 5 In xenograft studies, stable depletion of DYRK2 significantly accelerated tumor growth. 4 To directly address The results revealed that the loss of CDK14 expression significantly inhibited tumor growth in DYRK2-depleted tumors ( Figure 3D ).
These findings indicate that tumor cell proliferation and invasion are regulated by DYRK2 via CDK14.
| Androgen receptor is a dual-specificity
tyrosine-regulated kinase 2-dependent transcriptional activator of cyclin-dependent kinase 14
Cyclin-dependent kinase 14 was found to be regulated at the mRNA level by DYRK2. We therefore explored the transcription factors involved in the regulation of CDK14 expression by DYRK2. We used two approaches to predict the identity of these transcription factors:
analysis of upstream transcription factors and binding site analysis. proteins as putative transcription factors that have binding sites in the promoter regions of genes that display expression changes in response to DYRK2. We compared the microarray data from control versus DYRK2-depleted cells, and predicted upstream transcription factors using the TRANSFAC database (described in the Materials and Methods). We also identified 370 transcription factors that have binding sites less than 3 kb upstream of the CDK14 gene using the MAPPER database (http://genome.ufl.edu/mapper) . 16 Our previous study showed that AR was a DYRK2-dependent transcriptional activator. 8 In this context, we also identified 5 binding sites of AR within 3 kb upstream of the CDK14 gene using the MAPPER database. AR was also identified by analysis of upstream transcription factors. We thus focused on one of the high-scoring genes, AR ( Figure S2A,B) .
Real-time RT-PCR and western blotting revealed that inhibition of AR activity using the AR inhibitor MDV3100 decreased both mRNA and protein levels of CDK14 in shDYRK2 and GFP control cells (Figure 4A-D) . Of note, silencing or overexpression of DYRK2 had little effect on AR expression in human breast cancer cell lines, such as MCF-7 and MDA-MB-231 ( Figure S2C,D) . In contast, knocking down DYRK2 induced AR transcription activity in MCF-7 cells ( Figure S2E ).
We confirmed that DYRK2 depletion in MCF-7 cells decreased the levels of CDK14 mRNA in a MDV3100 concentration-dependent manner ( Figure 4E ). These results imply the possibility that AR acts as a transcriptional activator for CDK14 and is dependent on DYRK2. To determine the clinical relevance of DYRK2 and CDK14, we examined breast cancer specimens ( Figure 5A ; Figure S3 and Table S2 ).
F I G U R E 4 Androgen receptor (AR) is
Both CDK14 and DYRK2 were detected immunohistochemically in the cytoplasm of cancer cells. We analyzed specimens from 60 patients with invasive ductal carcinomas. We uncovered an inverse correlation between the expression levels of DYRK2 and CDK14
( Figure 5B ). Taken together, these findings indicate that DYRK2 suppresses tumor cell proliferation and invasion by inhibiting CDK14
transcription. In contrast, reduced DYRK2 expression in invasive ductal carcinoma likely promotes tumor cell proliferation and invasion by modulating CDK14 expression via AR ( Figure 5C ).
| DISCUSSION
In this study, we demonstrated that DYRK2 is a regulator of breast cancer progression. DYRK2 suppresses cancer cell proliferation and invasion by inhibiting the transcription of CDK14. The following evidence supports this conclusion. First, CDK14 mRNA and protein levels increased in DYRK2-depleted cells (Figure 1 ). Second, low DYRK2 expression was associated with increased proliferation in breast cancer cell lines. In contrast, high DYRK2 expression was associated with decreased cell proliferation (Figure 2) . Third, cancer cell proliferation and invasion were suppressed by inhibition of CDK14 expression in DYRK2-depleted cells (Figure 3) . Fourth, it is conceivable that AR could promote transcription of CDK14 in DYRK2-depleted cells (Figure 4) . Finally, CDK14 and DYRK2 expression were inversely correlated in human breast cancer tissues ( Figure 5 ).
F I G U R E 5
Clinical relevance of cyclindependent kinase 14 (CDK14) and DYRK2 in breast cancer. (A) Breast cancer tissues were immunostained with anti-DYRK2 or anti-CDK14 antibodies. Images were obtained at 400 9 magnification. Scale bar represents 50 lm. (B) The correlation between DYRK2 and CDK14 expression was assessed. The P-value was calculated using the v 2 -test. (C) DYRK2 suppresses tumor cell proliferation and invasion by inhibiting CDK14 transcription, and reduced DYRK2 expression in invasive ductal carcinoma promotes tumor cell proliferation and invasion through CDK14 expression via transcriptional regulation by AR Using a microarray, we identified CDK14 as a target of DYRK2, which is, to the best of our knowledge, the first time this has been demonstrated. Previous studies showed that CDK14 is an oncogene. [11] [12] [13] [14] Previous studies have also described the knockdown phenotype and downstream targets of CDK14. [11] [12] [13] 15 However, our study demonstrated that DYRK2 is an upstream regulator of CDK14. We demonstrate the possibility that AR acts as a transcriptional activator of CDK14, and it is dependent on DYRK2 expression. AR inhibitor partially reduced CDK14 transcription, suggesting that other molecules would be also involved. We previously reported that AR acts as a transcriptional activator of KLF4, and it is also dependent on DYRK2. 8 The mechanism underlying DYRK2-mediated AR promoter binding remains unclear. Further research is needed to uncover this mechanism.
The AR inhibitor MDV3100 affects the androgen receptor signaling pathway in multiple steps: (i) inhibiting binding of androgens to AR; (ii) inhibiting nuclear translocation of AR; and (iii) inhibiting association of AR with DNA. 26 When AR is bound to MDV3100, it adopts a conformation incapable of DNA binding or of coactivator recruitment. 27 Overall, AR is expressed in approximately 70-80% of breast cancers. 28, 29 A recent review article reported that androgen receptor-targeted therapies have shown promising preliminary results in breast cancer. 30 There was a limitation in the current study. was not only surgery but also chemotherapy.
In conclusion, our results delineate a novel mechanism for cancer cell proliferation and invasion through the DYRK2-AR-CDK14 axis.
Restoration of the expression and function of DYRK2 is a potential therapeutic strategy for treating breast cancer.
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